Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
4.030
-0.060 (-1.47%)
Sep 16, 2025, 4:00 PM EDT - Market closed
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
274.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OMER News
- 14 days ago - Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program - Business Wire
- 4 weeks ago - Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Omeros Corporation Reports Second Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 - Business Wire
- 7 weeks ago - Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering - Business Wire
- 2 months ago - Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA - Business Wire
- 3 months ago - Omeros Announces Webcast Details for Annual Meeting of Shareholders - Business Wire
- 3 months ago - Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga